| abstract |
The invention features interferon-free therapies for the treatment of HCV. Preferably, treatment is for a short period of time, such as not exceeding 12 weeks. In one aspect, therapy comprises administering at least two direct-acting antiviral agents and ribavirin to a subject infected with HCV. For example, the therapy comprises administering to the subject an effective dose of Therapeutic Agent 1, Therapeutic Agent 2 (or Therapeutic Agent 3), a cytochrome P450 inhibitor (eg, ritonavir), and ribavirin. |